Edition:
United States

Alnylam Pharmaceuticals Inc (ALNY.O)

ALNY.O on Nasdaq

117.04USD
25 Sep 2017
Change (% chg)

$3.24 (+2.85%)
Prev Close
$113.80
Open
$112.40
Day's High
$118.30
Day's Low
$112.13
Volume
2,091,450
Avg. Vol
1,235,793
52-wk High
$118.40
52-wk Low
$31.38

Select another date:

Wed, Sep 20 2017

Alnylam's RNAi drug succeeds in key study, shares soar

Alnylam Pharmaceuticals Inc's RNAi-based drug that targets a rare genetic disease met the main goal of a key study, in a breakthrough for the new class of medicines that works by blocking disease-causing proteins.

UPDATE 4-Alnylam's RNAi drug succeeds in key study, shares soar

* $1 bln peak sales expected for patisiran in 2023 - Credit Suisse

BRIEF-Alnylam's genetic disease drug meets main goal in phase 3 study

* Sanofi and Alnylam report positive topline results from APOLLO phase 3 study of patisiran in Hereditary ATTR (HATTR) amyloidosis patients with polyneuropathy

Alnylam's genetic disease drug meets main goal in key study

Sept 20 Alnylam Pharmaceuticals Inc said on Wednesday its drug met the main goal in a late-stage study in patients suffering from a life-threatening genetic disease.

Alnylam stock plummets after patient death in hemophilia study

Alnylam Pharmaceuticals Inc said on Thursday it stopped giving doses of its experimental drug for a rare bleeding disorder to patients enrolled in its clinical studies after one patient died, sending its shares sharply down.

UPDATE 2-Alnylam stock plummets after patient death in hemophilia study

* Alnylam says will resume trials as soon as possible (Adds details, analyst's comments)

BRIEF-Sanofi alliance partner Alnylam gives update on fitusiran

* Sanofi-‍as disclosed by Alnylam, fatal thrombotic event occurred in patient with hemophilia without inhibitors enrolled in Phase 2 OLE study of fitusiran​ Source text for Eikon: Further company coverage:

Alnylam suspends bleeding disorder trial dosing after patient death

Sept 7 U.S. drug developer Alnylam Pharmaceuticals Inc said on Thursday it stopped giving doses of its experimental drug for a rare bleeding disorder to patients enrolled in its clinical studies following a patient's death.

BRIEF-Alnylam provides pipeline update on Fitusiran and Givosiran investigational RNAI therapeutic programs

* Alnylam provides pipeline update on Fitusiran and Givosiran investigational RNAI therapeutic programs

BRIEF-Alnylam Pharmaceuticals reports Q2 adj loss per share $1.07

* Alnylam Pharmaceuticals reports second quarter 2017 financial results and highlights recent period activity

Select another date: